Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. It also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. The company is headquartered in Naples, Florida.
Metrics to compare | ENVB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipENVBPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.3x | −1.2x | −0.5x | |
PEG Ratio | 0.00 | −0.03 | 0.00 | |
Price/Book | 0.8x | 0.6x | 2.6x | |
Price / LTM Sales | - | 2.3x | 3.1x | |
Upside (Analyst Target) | - | 115.4% | 47.8% | |
Fair Value Upside | Unlock | −1.3% | 6.9% | Unlock |